Direct_NP PCR_NP Detection_NP of_IN Burkholderia_NP cepacia_NP Complex_NP and_CC Identification_NP of_IN Its_PP$ Genomovars_NNS by_IN Using_VBG Sputum_NP as_IN Source_NN of_IN DNA_NP We_PP developed_VBD a_DT nested_VBN PCR_NP assay_NN that_WDT detects_VBZ the_DT recA_NN gene_NN of_IN the_DT Burkholderia_NP cepacia_NN complex_NN in_IN sputum_NN ._SENT The_DT product_NN of_IN the_DT first_JJ PCR_NP round_NN is_VBZ also_RB used_VBN to_TO identify_VB the_DT genomovar_NN of_IN the_DT pathogen_NN ._SENT The_DT protocol_NN achieves_VBZ high_JJ sensitivity_NN and_CC specificity_NN with_IN simple_JJ interpretation_NN of_IN genomovar_JJ status_NN ._SENT Burkholderia_NP cepacia_NP is_VBZ a_DT multiresistant_JJ and_CC transmissible_JJ opportunistic_JJ pathogen_NN that_WDT frequently_RB impairs_VBZ the_DT clinical_JJ state_NN of_IN patients_NNS with_IN cystic_JJ fibrosis_NN (_( CF_NP )_) ._SENT The_DT group_NN of_IN B._NP cepacia_NP complex_NN (_( BCC_NP )_) organisms_NNS consists_VBZ of_IN eight_CD genomovars_NNS associated_VBN with_IN different_JJ levels_NNS of_IN virulence_NN and_CC patient-to-patient_JJ transmissibility_NN :_: B._NP cepacia_NP genomovar_NN I_PP ,_, B._NP multivorans_NP (_( genomovar_NP II_NP )_) ,_, B._NP cepacia_NP genomovar_NP III_NP ,_, B._NP stabilis_NP (_( genomovar_NP IV_NP )_) ,_, B._NP vietnamiensis_NP (_( genomovar_NN V_CD )_) ,_, B._NP cepacia_NP genomovar_NP VI_NP ,_, B._NP ambifaria_NP (_( genomovar_NP VII_NP )_) ,_, and_CC B._NP pyrrocinia_NN ._SENT To_TO reduce_VB the_DT probability_NN of_IN BCC_NP spreading_VBG among_IN patients_NNS with_IN CF_NP ,_, a_DT reliable_JJ early_JJ test_NN that_WDT detects_VBZ small_JJ quantities_NNS of_IN the_DT bacteria_NNS in_IN clinical_JJ samples_NNS is_VBZ needed_VBN ._SENT Conventional_JJ microbiological_JJ diagnostics_NNS of_IN the_DT BCC_NP based_VBN on_IN the_DT results_NNS of_IN culture_NN and_CC subsequent_JJ biochemical_JJ identification_NN is_VBZ insufficient_JJ for_IN this_DT purpose_NN because_IN of_IN the_DT potential_JJ risk_NN of_IN misidentification_NN or_CC false_JJ negativity_NN ._SENT Moreover_RB ,_, these_DT methods_NNS are_VBP not_RB able_JJ to_TO reliably_RB distinguish_VB the_DT genomovars_NNS of_IN the_DT BCC_NP ._SENT To_TO increase_VB the_DT sensitivity_NN and_CC specificity_NN of_IN diagnostic_JJ routines_NNS and_CC to_TO identify_VB the_DT genomovars_NNS ,_, use_NN of_IN molecular_JJ genetic_JJ methods_NNS is_VBZ inevitable_JJ ._SENT Two_CD target_NN genes_NNS are_VBP commonly_RB used_VBN for_IN BCC_NP analysis_NN :_: the_DT 16S_JJ rRNA_NN gene_NN and_CC the_DT recA_NN gene_NN ._SENT The_DT recA_NN gene_NN polymorphisms_NNS enable_VBP both_DT differentiation_NN of_IN the_DT BCC_NP from_IN other_JJ closely_RB related_VBN bacteria_NNS and_CC its_PP$ sorting_VBG into_IN genomovars_NNS ._SENT Moreover_RB ,_, the_DT differences_NNS in_IN the_DT recA_NN sequences_NNS within_IN genomovar_NN III_NP led_VBD to_TO the_DT establishment_NN of_IN two_CD recA_NN clusters_NNS designated_VBN III-A_NP and_CC III-B_NP ._SENT The_DT present_JJ study_NN sought_VBN (_( i_NP )_) to_TO develop_VB a_DT rapid_JJ diagnostic_JJ method_NN for_IN early_JJ detection_NN of_IN BCC_NP organisms_NNS and_CC determination_NN of_IN their_PP$ genomovars_NNS directly_RB from_IN sputum_NN and_CC (_( ii_NNS )_) to_TO assess_VB the_DT occurrence_NN of_IN the_DT BCC_NP genomovars_NNS in_IN Czech_JJ patients_NNS with_IN CF_NP ._SENT From_IN May_NP 2001_CD to_TO April_NP 2002_CD ,_, we_PP collected_VBD 211_CD sputum_NN samples_NNS from_IN 134_CD consecutive_JJ CF_NP patients_NNS attending_VBG the_DT Prague_NP CF_NP center_NN (_( 55_CD males_NNS ,_, 79_CD females_NNS ;_: age_NN range_NN ,_, 0_CD to_TO 33_CD years_NNS )_) ._SENT All_DT samples_NNS were_VBD examined_VBN for_IN the_DT presence_NN of_IN the_DT BCC_NP by_IN culture_NN and_CC our_PP$ novel_JJ PCR_NP protocol_NN ._SENT For_IN cultivation_NN ,_, specimens_NNS were_VBD liquefied_VBN with_IN a_DT homogenization_NN solution_NN (_( 0.9_CD %_NN NaCl_NP ,_, 50_CD mM_NP KH2PO4_NP ,_, 35_CD mM_NP NaOH_NP ,_, 1_CD %_NN N-acetyl-l-cysteine_NP )_) ,_, shaken_VBN for_IN 20_CD min_NN at_IN 800_CD rpm_NN ,_, and_CC cultured_VBN on_IN blood_NN ,_, chocolate_NN ,_, Endo_NP ,_, Sabouraud_NP ,_, and_CC MacConkey_NP agars_NNS ._SENT The_DT last_JJ 53_CD samples_NNS were_VBD also_RB cultured_VBN on_IN the_DT selective_JJ B._NP cepacia_NN agar_NN (_( Oxoid_NP ,_, Basingstoke_NP ,_, United_NP Kingdom_NP )_) that_WDT came_VBD into_IN use_NN during_IN the_DT study_NN ._SENT All_DT of_IN the_DT BCC_NP isolates_NNS were_VBD identified_VBN by_IN the_DT API_NP 20_CD NE_NN system_NN (_( Biomerieux_NP ,_, Marcy_NP l'Etoile_NP ,_, France_NP )_) in_IN accordance_NN with_IN the_DT supplier_NN 's_POS protocol_NN ._SENT For_IN PCR_NP analysis_NN ,_, sputum_NN was_VBD mixed_VBN with_IN an_DT equal_JJ volume_NN of_IN the_DT homogenization_NN solution_NN and_CC shaken_VBN for_IN 1_CD h_NN at_IN 800_CD rpm_NN ._SENT DNA_NP was_VBD extracted_VBN from_IN 100_CD mul_NN of_IN liquefied_VBN sputum_NN with_IN the_DT AMPLICOR_NP Respiratory_NP Specimen_NP Preparation_NP Kit_NP (_( Roche_NP ,_, Indianapolis_NP ,_, Ind._NP )_) in_IN accordance_NN with_IN the_DT manufacturer_NN 's_POS instructions_NNS ._SENT To_TO check_VB the_DT DNA_NN content_NN in_IN extraction_NN aliquots_NNS ,_, real-time_JJ PCR_NP quantitation_NN of_IN the_DT human_JJ albumin_NN gene_NN as_IN an_DT equivalent_NN of_IN the_DT human_JJ DNA_NN content_NN was_VBD done_VBN on_IN an_DT ABI_NP 7700_CD system_NN (_( Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) ._SENT Samples_NNS with_IN albumin_NN gene_NN quantities_NNS below_IN the_DT fifth_JJ percentile_NN of_IN the_DT first_JJ 100_CD assays_NNS were_VBD re-extracted_JJ ._SENT To_TO detect_VB the_DT open_JJ reading_NN frame_NN of_IN the_DT BCC_NP recA_NN gene_NN ,_, DNA_NP extracts_VBZ were_VBD subjected_VBN to_TO nested_VBN PCRs_NNS ._SENT For_IN the_DT first_JJ PCR_NP round_NN ,_, the_DT Taq_NP PCR_NP Core_NP Kit_NP (_( Qiagen_NP ,_, Hilden_NP ,_, Germany_NP )_) was_VBD used_VBN ._SENT The_DT PCRs_NN were_VBD carried_VBN out_RP in_IN duplicate_NN in_IN a_DT total_JJ volume_NN of_IN 20_CD mul_NN with_IN 1x_NP PCR_NP buffer_NN ,_, 1x_NP solution_NN Q_NP (_( Qiagen_NP ,_, Hilden_NP ,_, Germany_NP )_) ,_, 2_CD mM_NP MgCl2_NP ,_, 200_CD muM_NN (_( each_DT )_) deoxynucleoside_NN triphosphate_NN ,_, 14_CD pmol_NN (_( each_DT )_) of_IN primers_NNS BCR1_NP and_CC BCR2_NP ,_, 1_CD U_NP of_IN Taq_NP polymerase_NN ,_, and_CC 1_CD mul_NN of_IN the_DT DNA_NP extract_NN ._SENT The_DT PCR_NP program_NN was_VBD run_VBN on_IN a_DT GeneAmp_JJ 9700_CD thermocycler_NN (_( Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) :_: initial_JJ denaturation_NN for_IN 2_CD min_NN at_IN 94C_NN ;_: 30_CD three-temperature_NN cycles_NNS of_IN 30_CD s_NNS at_IN 94C_NN ,_, 45_CD s_NNS at_IN 62C_JJ ,_, and_CC 90_CD s_NNS at_IN 72C_NP ;_: and_CC a_DT final_JJ extension_NN of_IN 5_CD min_NN at_IN 72C_NP ._SENT The_DT second_JJ round_NN of_IN the_DT nested_VBN PCR_NP was_VBD performed_VBN with_IN 1x_NP PCR_NP buffer_NN (_( Promega_NP )_) ,_, 2_CD mM_NP MgCl2_NP ,_, 200_CD muM_NN (_( each_DT )_) deoxynucleoside_NN triphosphate_NN ,_, 10_CD pmol_NN (_( each_DT )_) of_IN inner_JJ recA_NN primers_NNS REC-IN-5_NP and_CC BCRBM2_NP ,_, 0.5_CD U_NP of_IN Taq_NP polymerase_NN (_( Promega_NP ,_, Madison_NP ,_, Wis._NP )_) ,_, and_CC 0.5_CD mul_NN of_IN the_DT first-round_NP PCR_NP product_NN ._SENT The_DT amplification_NN profile_NN consisted_VBN of_IN 25_CD three-temperature_NN cycles_NNS of_IN 30_CD s_NNS (_( for_IN denaturation_NN )_) at_IN 94C_NN ;_: 45_CD s_NN (_( for_IN annealing_VBG )_) at_IN 67C_JJ (_( first_RB 5_CD cycles_NNS )_) ,_, 65C_JJ (_( next_JJ 5_CD cycles_NNS )_) ,_, and_CC 63C_JJ (_( remaining_VBG 15_CD cycles_NNS )_) ;_: and_CC 60_CD s_NNS (_( for_IN synthesis_NN )_) at_IN 72C_NP ._SENT A_DT final_JJ extension_NN step_NN of_IN 5_CD min_NN at_IN 72C_NP followed_VBD ._SENT The_DT PCR_NP products_NNS of_IN both_DT rounds_NNS were_VBD run_VBN on_IN a_DT 2_CD %_NN agarose_NN gel_NN in_IN 0.5_CD %_NN Tris-borate-EDTA_NP buffer_NN for_IN 20_CD min_NN at_IN 10_CD V/cm_NP ._SENT TABLE_NN 1_CD |_SYM Primers_NP used_VBN in_IN this_DT study_NN In_IN the_DT BCC-positive_JJ samples_NNS ,_, products_NNS of_IN the_DT first_JJ round_NN were_VBD also_RB used_VBN for_IN genomovar_JJ status_NN determination_NN ._SENT The_DT PCR_NP product_NN was_VBD diluted_VBN 1:10,000_CD (_( for_IN samples_NNS positive_JJ in_IN the_DT first_JJ PCR_NP round_NN )_) or_CC 1:100_CD (_( for_IN samples_NNS that_WDT yielded_VBD a_DT signal_NN only_RB in_IN the_DT second_JJ PCR_NP round_NN )_) with_IN deionized_JJ ,_, double-distilled_JJ water_NN ._SENT The_DT PCR_NP setup_NN was_VBD identical_JJ to_TO that_DT of_IN the_DT second_JJ round_NN ;_: the_DT genomovar_JJ specificity_NN of_IN the_DT eight_CD reactions_NNS was_VBD maintained_VBN by_IN the_DT use_NN of_IN respective_JJ sequence-specific_JJ primers_NNS ._SENT New_JJ primer_NN pairs_NNS were_VBD designed_VBN to_TO identify_VB B._NP multivorans_NP (_( C-2_NP )_) ,_, genomovar_NP VI_NP (_( C-6_NP )_) ,_, and_CC B._NP ambifaria_NP (_( C-7_JJ )_) ._SENT To_TO check_VB the_DT sensitivity_NN and_CC specificity_NN of_IN the_DT assays_NNS ,_, we_PP used_VBD strains_NNS from_IN the_DT BCC_NP strain_NN panel_NN completed_VBN with_IN genomovar_JJ VI_NP and_CC B._NP ambifaria_NN strains_NNS from_IN the_DT Laboratorium_NP voor_NP Microbiologie_NP ,_, Ghent_NP ,_, Belgium_NP ._SENT The_DT recently_RB described_VBN species_NNS B._NP pyrrocinia_NNS was_VBD not_RB tested_VBN ._SENT Results_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT Each_DT strain_NN was_VBD correctly_RB identified_VBN ;_: moreover_RB ,_, our_PP$ new_JJ 3_CD '_POS primers_NNS eliminated_VBD the_DT previously_RB described_VBN cross-reactivity_NN between_IN B._NP multivorans_NNS and_CC genomovar_JJ VI_NP ._SENT We_PP also_RB tested_VBD for_IN reactivity_NN with_IN other_JJ bacteria_NNS possibly_RB present_JJ in_IN CF_NP sputum_NN (_( i.e._FW ,_, Staphylococcus_NP aureus_NN ,_, Pseudomonas_NP aeruginosa_NP ,_, Haemophilus_NP influenzae_NP ,_, Stenotrophomonas_NP maltophilia_NP ,_, Alcaligenes_NP xylosoxidans_NP ,_, Ralstonia_NP pickettii_NP ,_, B._NP gladioli_NNS ,_, Chryseobacterium_NN meningosepticum_NN ,_, and_CC Delftia_NP acidovorans_NNS )_) ._SENT No_DT reactivity_NN was_VBD observed_VBN for_IN either_CC the_DT generic_JJ C-IN_NP primer_NN mixture_NN (_( used_VBN in_IN the_DT second_JJ round_NN of_IN the_DT nested_VBN PCR_NP )_) or_CC the_DT genomovar-specific_JJ primer_NN pairs_NNS ._SENT To_TO determine_VB the_DT sensitivity_NN of_IN the_DT nested_VBN PCR_NP ,_, the_DT procedure_NN described_VBN by_IN McDowell_NP et_FW al._FW was_VBD applied_VBN to_TO strains_NNS LMG_NP 16656_CD (_( genomovar_NN III-A_NP )_) and_CC LMG_NP 13010_NP (_( B._NP multivorans_NNS )_) ._SENT The_DT detection_NN limit_NN of_IN the_DT nested_VBN PCR_NP was_VBD 103_CD CFU/ml_NN of_IN sputum_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Genomovar-specific_JJ reactions_NNS on_IN BCC_NP reference_NN strains_NNS ATCC_NP 25416_CD (_( A_NP )_) ,_, LMG_NP 16660_CD (_( B_NP )_) ,_, LMG_NP 16656_CD (_( C_NP )_) ,_, LMG_NP 14294_CD (_( E_NP )_) ,_, LMG_NP 10929_CD (_( F_NN )_) ,_, LMG_NP 18941_CD (_( G_NP )_) ,_, and_CC LMG_NP 19182_NP (_( H_NP )_) and_CC a_DT clinical_JJ sample_NN of_IN genomovar_NN III-B_NP (_( D_NP )_) ._SENT Genomovar-specific_JJ reactions_NNS on_IN BCC_NP reference_NN strains_NNS ATCC_NP 25416_CD (_( A_NP )_) ,_, LMG_NP 16660_CD (_( B_NP )_) ,_, LMG_NP 16656_CD (_( C_NP )_) ,_, LMG_NP 14294_CD (_( E_NP )_) ,_, LMG_NP 10929_CD (_( F_NN )_) ,_, LMG_NP 18941_CD (_( G_NP )_) ,_, and_CC LMG_NP 19182_NP (_( H_NP )_) and_CC a_DT clinical_JJ sample_NN of_IN genomovar_NN III-B_NP (_( D_NP )_) ._SENT The_DT lanes_NNS contained_VBD sequence-specific_JJ primer_JJR PCR_NP products_NNS of_IN the_DT genomovars_NNS ._SENT Lanes_NNS :_: 1_LS ,_, genomovar_NN I_PP ;_: 2_LS ,_, B._NP multivorans_NNS ;_: 3a_NP ,_, genomovar_NP III-A_NP ;_: 3b_JJ ,_, genomovar_JJ III-B_NN ;_: 4_LS ,_, B._NP stabilis_NP ;_: 5_LS ,_, B._NP vietnamiensis_NN ;_: 6_CD ,_, genomovar_NP VI_NP ;_: 7_CD ,_, B._NP ambifaria_NNS ;_: IN_IN ,_, generic_JJ detection_NN of_IN the_DT BCC_NP species_NN ._SENT Molecular_JJ size_NN markers_NNS (_( 100-bp_JJ ladder_NN )_) were_VBD run_VBN in_IN lane_JJ M._NP Two_NP hundred_CD eleven_NN sputum_NN samples_NNS from_IN 134_CD CF_NP patients_NNS were_VBD tested_VBN ._SENT By_IN culture_NN techniques_NNS ,_, the_DT BCC_NP organisms_NNS were_VBD recovered_VBN from_IN 89_CD (_( 42_CD %_NN )_) of_IN 211_CD samples_NNS ._SENT Comparing_VBG results_NNS of_IN growth_NN on_IN the_DT nonselective_JJ agars_NNS and_CC selective_JJ B._NP cepacia_NN medium_NN ,_, we_PP found_VBD no_DT difference_NN in_IN the_DT number_NN of_IN BCC_NP organisms_NNS recovered_VBD ._SENT By_IN the_DT nested-PCR_NN protocol_NN ,_, 110_CD samples_NNS (_( 52_CD %_NN )_) were_VBD determined_VBN to_TO be_VB BCC_NP positive_NN ,_, of_IN which_WDT 28_CD yielded_VBD a_DT signal_NN only_RB in_IN the_DT second_JJ PCR_NP round_NN ._SENT Of_IN the_DT 134_CD patients_NNS examined_VBD ,_, the_DT BCC_NP was_VBD detected_VBN in_IN 49_CD patients_NNS by_IN culture_NN whereas_IN it_PP was_VBD detected_VBN in_IN 67_CD patients_NNS by_IN PCR_NP ._SENT Thus_RB ,_, 18_CD more_JJR CF_NP patients_NNS were_VBD found_VBN to_TO be_VB BCC_NP positive_JJ by_IN PCR_NP than_IN by_IN cultivation_NN ._SENT A_DT nested_VBN or_CC seminested_JJ design_NN is_VBZ known_VBN to_TO increase_VB PCR_NP sensitivity_NN ._SENT The_DT improvement_NN in_IN sensitivity_NN over_IN the_DT nonnested_JJ setup_NN was_VBD evident_JJ in_IN 28_CD positive_JJ samples_NNS that_WDT were_VBD found_VBN to_TO be_VB positive_JJ only_RB after_IN the_DT second_JJ round_NN of_IN PCR_NP ._SENT This_DT represents_VBZ 25_CD %_NN of_IN the_DT 110_CD positive_JJ samples_NNS ._SENT Similarly_RB ,_, the_DT superiority_NN of_IN two_CD PCR_NP rounds_NNS was_VBD demonstrated_VBN by_IN Moore_NP et_FW al._FW ,_, who_WP employed_VBD a_DT seminested_JJ approach_NN for_IN detection_NN of_IN B._NP multivorans_NNS and_CC genomovar_JJ III_NP ._SENT Although_IN the_DT sensitivity_NN of_IN the_DT reported_VBN seminested_JJ strategy_NN was_VBD 1_CD order_NN of_IN magnitude_NN greater_JJR than_IN the_DT sensitivity_NN of_IN the_DT present_JJ method_NN ,_, our_PP$ protocol_NN offers_VBZ the_DT sorting_VBG of_IN BCC_NP organisms_NNS into_IN seven_CD genomovars_NNS ._SENT To_TO further_RBR minimize_VB the_DT risk_NN of_IN false_JJ negativity_NN ,_, we_PP checked_VBD the_DT yields_NNS of_IN DNA_NN extraction_NN by_IN using_VBG real-time_JJ quantification_NN of_IN human_JJ genome_NN equivalents_NNS per_IN microliter_NN of_IN DNA_NP ._SENT If_IN human_JJ DNA_NN was_VBD not_RB present_JJ in_IN a_DT sufficient_JJ quantity_NN in_IN the_DT extract_NN ,_, failure_NN of_IN DNA_NP extraction_NN was_VBD highly_RB probable_JJ since_IN sputum_NN contains_VBZ large_JJ quantities_NNS of_IN leukocytes_NNS ._SENT As_RB regards_VBZ the_DT genomovar_JJ identification_NN of_IN BCC_NP organisms_NNS ,_, 62_CD patients_NNS (_( 92.5_CD %_NN )_) were_VBD colonized_VBN by_IN genomovar_JJ III_NP ,_, recA_NN group_NN III-A_NP ;_: 3_CD were_VBD colonized_VBN by_IN genomovar_JJ III_NP ,_, recA_NN group_NN III-B_NN ;_: and_CC 2_CD were_VBD colonized_VBN by_IN B._NP multivorans_NNS ._SENT None_NN of_IN the_DT patients_NNS was_VBD infected_VBN by_IN two_CD or_CC more_JJR genomovars_NNS ,_, and_CC replacement_NN of_IN one_CD genomovar_NN by_IN another_DT was_VBD not_RB observed_VBN during_IN the_DT study_NN period_NN ._SENT In_IN addition_NN to_TO analysis_NN of_IN clinical_JJ samples_NNS ,_, we_PP examined_VBD 44_CD BCC_NP isolates_NNS recovered_VBD from_IN sputum_NN samples_NNS of_IN 36_CD Czech_JJ CF_NP patients_NNS collected_VBN from_IN 1997_CD to_TO 1999_CD and_CC archived_VBN at_IN the_DT National_NP Institute_NP of_IN Public_NP Health_NP ,_, Prague_NP ,_, Czech_NP Republic_NP ._SENT All_DT of_IN them_PP were_VBD identified_VBN as_IN genomovar_JJ III_NP ,_, recA_NN group_NN III-A_NP ,_, which_WDT has_VBZ been_VBN previously_RB associated_VBN with_IN the_DT most_RBS severe_JJ course_NN of_IN the_DT infection_NN caused_VBN by_IN the_DT BCC_NP ._SENT The_DT almost_RB absolute_JJ uniformity_NN of_IN the_DT BCC_NP genomovar_NN spectrum_NN in_IN the_DT Czech_JJ CF_NP community_NN is_VBZ alarming_JJ ,_, and_CC the_DT identical_JJ finding_NN among_IN the_DT archived_JJ samples_NNS suggests_VBZ a_DT possible_JJ epidemic_NN origin_NN of_IN the_DT infections_NNS ._SENT However_RB ,_, to_TO fully_RB explain_VB this_DT unfavorable_JJ phenomenon_NN ,_, further_JJR studies_NNS based_VBN on_IN molecular_JJ typing_VBG have_VB to_TO be_VB performed_VBN ._SENT In_IN conclusion_NN ,_, the_DT protocol_NN described_VBD herein_RB offers_VBZ rapid_JJ PCR_NP detection_NN of_IN BCC_NP in_IN sputum_NN and_CC identification_NN of_IN its_PP$ genomovars_NNS ._SENT Previous_JJ assays_NNS for_IN direct_JJ PCR_NP detection_NN of_IN the_DT BCC_NP in_IN sputum_NN were_VBD based_VBN on_IN amplification_NN of_IN the_DT 16S_JJ rRNA_NN gene_NN or_CC of_IN the_DT 16S-23S_JJ spacer_NN region_NN of_IN the_DT rRNA_NN operon_NN ._SENT Recently_RB ,_, McDowell_NP et_FW al._FW described_VBN PCR_NP of_IN the_DT recA_NN gene_NN followed_VBN by_IN restriction_NN fragment_NN length_NN polymorphism_NN (_( RFLP_NP )_) analysis_NN ,_, concluding_VBG that_IN the_DT recA_NN gene_NN is_VBZ a_DT more_RBR suitable_JJ target_NN than_IN the_DT 16S_JJ region_NN ._SENT However_RB ,_, the_DT PCR-RFLP_NP assay_NN can_MD yield_VB many_JJ different_JJ RFLP_NP patterns_NNS ,_, demanding_VBG attentive_JJ comparison_NN ._SENT On_IN the_DT contrary_NN ,_, the_DT algorithm_NN presented_VBD here_RB with_IN nested_VBN PCR_NP and_CC genomovar-specific_JJ recA_NN primers_NNS achieves_VBZ high_JJ sensitivity_NN and_CC specificity_NN with_IN simple_JJ interpretation_NN of_IN genomovar_JJ results_NNS ._SENT 